Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment
strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the …

The prevention of cardiac life-threatening ventricular fibrillation and stroke-provoking atrial
fibrillation remains a serious global clinical issue, with ongoing need for novel approaches …

Dilated cardiomyopathy (DCM) is a major risk factor for heart failure and is associated with
the development of life-threatening cardiac arrhythmias. Using a patient-specific induced …

Atrial fibrillation (AF) is the most common arrhythmia, increasing with age and comorbidities.
Obstructive sleep apnea (OSA) is a chronic sleep disorder more common in older men. It …

The Wnt/β-catenin signaling pathway is a classical Wnt pathway that regulates the stability
and nuclear localization of β-catenin and plays an important role in adult heart development …

Clinicians accept that there are many unknowns when we make diagnostic and therapeutic
decisions. Acceptance of uncertainty is essential for the pursuit of the profession: bedside …

Objective Patients with electrical injury are considered to be at high risk of cardiac
arrhythmias. Due to the small number of studies, there is no widely accepted guideline …

Aims Atrial fibrillation (AF) is associated with tachycardia-induced cellular electrophysiology
alterations which promote AF chronification and treatment resistance. Development of novel …

Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can
definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF) …

Background: Despite an increasing understanding of atrial fibrillation (AF) pathophysiology,
translation into mechanism-based treatment options is lacking. In atrial cardiomyocytes of …